Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof

Document Type

Patent

Publication Date

2-23-2021

Keywords

oregon; portland; chiles

Abstract

The present invention relates to the preparation and use in primates of whole organismvaccines in which the MEP pathway is disrupted such that synthesis of HMBPP by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active MEP pathway are used in vaccine methods, the .gamma..delta. T cell response dominates, potentially clearing the vaccine strain via .gamma..delta. T cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of CD4.sup.+ and CD8.sup.+ .alpha..beta. T cell responses, specific for listerial-encoded antigens. By disrupting the MEP pathway, activation and expansion of .gamma..delta. T cells is limited in the recipient primate, resulting in resulting in an increase in the magnitude and duration of inflammation and in the magnitude and duration of antigen presentation by the cellular vaccine.

Specialty/Research Institute

Pharmacy

Location

United States

Comments

Patent Number: 10,925,945

Assignee

PROVIDENCE HEALTH & SERVICES-OREGON (Portland, OR)

Family ID

55747226

Serial Number

15/519,114

Link to Full Text

Share

COinS